Aker BioMarine is a biotech innovator and Antarctic krill-harvesting company, dedicated to improving human and planetary health. The company develops krill-based ingredients for nutraceuticals, aquaculture, and animal feed applications. In November 2020, inspired by the breakthrough science that identified how EPA/DHA is transported into the brain, Aker BioMarine introduced LYSOVETA™, lyso-phosphatidylcholine (LPC)-bound EPA/DHA. Recent scientific findings showing that EPA/DHA is transported into the brain, in the form of LPC-bound EPA/DHA, give us a unique opportunity to further explore the effects EPA/DHA have on brain and eye health; both throughout the normal lifespan and in diseased conditions. With LYSOVETA™ Aker BioMarine is dedicated to developing further insights and unlocking the potential for LPC-bound EPA/DHA in improving human health.